Level Biotechnology Total Assets
Level Biotechnology total assets. Based on the latest financial reports, Level Biotechnology (3118) holds total assets worth NT$799.85 Million TWD (≈ $25.20 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 3118 company net worth for the company's overall valuation and market capitalisation.
Total Assets of Level Biotechnology (2017–2024)
Total assets of Level Biotechnology from 2017 to 2024. This chart illustrates how Level Biotechnology's total assets have evolved over time, based on quarterly financial data. See today's stock price for Level Biotechnology for real-time trading data and today's change.
Level Biotechnology - Asset Composition Analysis
Level Biotechnology Total Assets Breakdown (December 2024)
Level Biotechnology total assets breakdown as of December 2024. Level Biotechnology's total assets of NT$799.85 Million consist of 58.5% current assets and 41.5% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 30.6% |
| Accounts Receivable | NT$112.09 Million | 13.6% |
| Inventory | NT$98.09 Million | 11.9% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Level Biotechnology's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Level Biotechnology (3118) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Level Biotechnology's current assets represent 58.5% of total assets in 2024, a decrease from 74.6% in 2017.
- Cash Position: Cash and equivalents constituted 30.6% of total assets in 2024, down from 43.8% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 13.6% of total assets.
Level Biotechnology Competitors by Total Assets
Key competitors of Level Biotechnology based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Level Biotechnology - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.93 | 2.65 | 2.71 |
| Quick Ratio | 1.53 | 2.23 | 2.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$210.42 Million | NT$397.96 Million | NT$383.95 Million |
Level Biotechnology - Advanced Valuation Insights
This section examines the relationship between Level Biotechnology's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.89 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 0.5% |
| Total Assets | NT$827.11 Million |
| Market Capitalization | $31.08 Million USD |
Valuation Analysis
Below Book Valuation: The market values Level Biotechnology's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Level Biotechnology's assets grew by 0.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Level Biotechnology (2017–2024)
The table below shows the annual total assets of Level Biotechnology from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$827.11 Million ≈ $26.06 Million |
+0.54% |
| 2023-12-31 | NT$822.67 Million ≈ $25.92 Million |
+1.25% |
| 2022-12-31 | NT$812.53 Million ≈ $25.60 Million |
+3.16% |
| 2021-12-31 | NT$787.62 Million ≈ $24.81 Million |
+1.89% |
| 2020-12-31 | NT$772.99 Million ≈ $24.35 Million |
+3.04% |
| 2019-12-31 | NT$750.18 Million ≈ $23.63 Million |
+10.26% |
| 2018-12-31 | NT$680.39 Million ≈ $21.44 Million |
-7.09% |
| 2017-12-31 | NT$732.31 Million ≈ $23.07 Million |
-- |
About Level Biotechnology
Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. It markets and distributes biomedical precision equipment. The company also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. In addition, it offers preclinical research services to the bio… Read more